Login to Your Account

Pozen's Lead Stomach-Friendly Aspirin Positive in Phase III

By Catherine Shaffer
Staff Writer

Friday, March 23, 2012
Relief may be on the way for cardiac patients who can't tolerate aspirin. Pozen Inc., of Chapel Hill, N.C., reported positive results from two Phase III pivotal trials showing that treatment with PA32540, a formulation of aspirin combined with the proton pump inhibitor omeprazole, led to a significant reduction in gastric ulcers compared to enteric-coated aspirin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription